A Novel Ferroptosis-related Gene Signature for Clinically Predicting Recurrence After Hepatectomy of Hepatocellular Carcinoma Patients
Overview
Affiliations
High recurrence rate in HCC is the primary cause of the poor prognosis after hepatectomy. Therefore, in this study, we aimed to construct a gene signature for predicting the recurrence rate in HCC. The mRNA expression profiles and clinical information of HCC patients from GEO and TCGA databases were used, and ferroptosis-related gene list was obtained from the FerrDb database. We identified 39 ferroptosis-related genes (FDEGs) that were differentially expressed between HCC samples and normal tissues from the GSE14520 dataset. The univariate and multivariate Cox regression analyses were employed to construct a prognostic signature. Seven FDEGs (MAPK9, SLC1A4, PCK2, ACSL3, STMN1, CDO1, and CXCL2) were included to construct a risk model, which was validated in the TCGA dataset. Patients in high-risk groups exhibited a significantly poor prognosis compared with patients in low-risk groups in both the training set (GSE14520 cohort) and the validation set (TCGA cohort). Multivariate cox regression analyses demonstrated that the 7-gene signature was an independent risk factor for RFS in HCC patients. KEGG analysis showed that FDEGs were mainly enriched in Ferroptosis, Hepatocellular carcinoma pathway, and MAPK signaling pathway. GSEA analysis suggested that the high-risk group was correlated with multiple oncogenic signatures and invasive-related pathways. These results indicated that this risk model can accurately predict recurrence after hepatectomy and offer novel research directions for personalized treatment in HCC patients.
Zheng J, Gong J Anal Cell Pathol (Amst). 2025; 2025:1115184.
PMID: 39949345 PMC: 11824774. DOI: 10.1155/ancp/1115184.
Zhuo Z, Wu H, Xu L, Ji Y, Li J, Liu L Apoptosis. 2025; .
PMID: 39904860 DOI: 10.1007/s10495-025-02080-6.
Panettieri E, Campisi A, De Rose A, Mele C, Giuliante F, Vauthey J Cancers (Basel). 2024; 16(12).
PMID: 38927889 PMC: 11201456. DOI: 10.3390/cancers16122183.
Yang Q, Zhuo Z, Qiu X, Luo R, Guo K, Wu H J Transl Med. 2024; 22(1):122.
PMID: 38297333 PMC: 10832138. DOI: 10.1186/s12967-024-04926-0.
Yang B, Ma Q, Hui Y, Gao X, Ma D, Li J Transl Cancer Res. 2024; 12(12):3327-3345.
PMID: 38192999 PMC: 10774034. DOI: 10.21037/tcr-23-685.